Cargando…

NK cell expression of natural cytotoxicity receptors may determine relapse risk in older AML patients undergoing immunotherapy for remission maintenance

In a phase IV trial, eighty-four patients (age 18–79) with acute myeloid leukemia (AML) in first complete remission (CR) received cycles of immunotherapy with histamine dihydrochloride (HDC) and low-dose human recombinant interleukin-2 (IL-2) to prevent relapse in the post-consolidation phase. Aspec...

Descripción completa

Detalles Bibliográficos
Autores principales:	Martner, Anna, Rydström, Anna, Riise, Rebecca E., Aurelius, Johan, Brune, Mats, Foà, Robin, Hellstrand, Kristoffer, Thorén, Fredrik B.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2015
Materias:	Research Paper: Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4767453/ https://www.ncbi.nlm.nih.gov/pubmed/26544512

Ejemplares similares

Role of natural killer cell subsets and natural cytotoxicity receptors for the outcome of immunotherapy in acute myeloid leukemia
por: Martner, Anna, et al.
Publicado: (2015)

Dynamics of cytotoxic T cell subsets during immunotherapy predicts outcome in acute myeloid leukemia
por: Sander, Frida Ewald, et al.
Publicado: (2016)

Role of regulatory T cells in acute myeloid leukemia patients undergoing relapse-preventive immunotherapy
por: Sander, Frida Ewald, et al.
Publicado: (2017)

Impact of IL-1β and the IL-1R antagonist on relapse risk and survival in AML patients undergoing immunotherapy for remission maintenance
por: Grauers Wiktorin, Hanna, et al.
Publicado: (2021)

Complete remission after the first cycle of induction chemotherapy determines the clinical efficacy of relapse‐preventive immunotherapy in acute myeloid leukaemia
por: Nilsson, Malin S., et al.
Publicado: (2019)

Impact of NK Cell Activating Receptor Gene Variants on Receptor Expression and Outcome of Immunotherapy in Acute Myeloid Leukemia
por: Hussein, Brwa Ali, et al.
Publicado: (2021)

Corrigendum: Impact of NK Cell Activating Receptor Gene Variants on Receptor Expression and Outcome of Immunotherapy in Acute Myeloid Leukemia
por: Hussein, Brwa Ali, et al.
Publicado: (2022)

Immunotherapy with HDC/IL-2 may be clinically efficacious in acute myeloid leukemia of normal karyotype
por: Nilsson, Malin S., et al.
Publicado: (2019)

NKG2A gene variant predicts outcome of immunotherapy in AML and modulates the repertoire and function of NK cells
por: Hussein, Brwa Ali, et al.
Publicado: (2023)

Role of the ERK Pathway for Oxidant-Induced Parthanatos in Human Lymphocytes
por: Akhiani, Ali A., et al.
Publicado: (2014)

Reactive oxygen species induced by therapeutic CD20 antibodies inhibit natural killer cell-mediated antibody-dependent cellular cytotoxicity against primary CLL cells
por: Werlenius, Olle, et al.
Publicado: (2016)

Impact of killer-immunoglobulin-like receptor and human leukocyte antigen genotypes on the efficacy of immunotherapy in acute myeloid leukemia
por: Bernson, E, et al.
Publicado: (2017)

Anti-Leukemic Properties of Histamine in Monocytic Leukemia: The Role of NOX2
por: Kiffin, Roberta, et al.
Publicado: (2018)

Histamine targets myeloid-derived suppressor cells and improves the anti-tumor efficacy of PD-1/PD-L1 checkpoint blockade
por: Grauers Wiktorin, Hanna, et al.
Publicado: (2018)

NOX2 in autoimmunity, tumor growth and metastasis
por: Martner, Anna, et al.
Publicado: (2018)

HLA-B*44 and the Bw4-80T motif are associated with poor outcome of relapse-preventive immunotherapy in acute myeloid leukemia
por: Komic, Hana, et al.
Publicado: (2023)

NOX2-Derived Reactive Oxygen Species in Cancer
por: Grauers Wiktorin, Hanna, et al.
Publicado: (2020)

IFNL4 Genotypes Predict Clearance of RNA Viruses in Rwandan Children With Upper Respiratory Tract Infections
por: Rugwizangoga, Belson, et al.
Publicado: (2019)

Repression of GSK3 restores NK cell cytotoxicity in AML patients
por: Parameswaran, Reshmi, et al.
Publicado: (2016)

Spontaneous Remission in an Older Patient with Relapsed FLT3 ITD Mutant AML
por: Vachhani, Pankit, et al.
Publicado: (2016)

NOX2 inhibition reduces oxidative stress and prolongs survival in murine KRAS-induced myeloproliferative disease
por: Aydin, Ebru, et al.
Publicado: (2018)

Low Incidence of Reinfection With Endemic Coronaviruses Diagnosed by Real-Time PCR
por: Ringlander, Johan, et al.
Publicado: (2020)

Reduced immunogenicity of a third COVID-19 vaccination among recipients of allogeneic hematopoietic stem cell transplantation
por: Einarsdottir, Sigrun, et al.
Publicado: (2022)

Impact of CYBA genotypes on severity and progression of multiple sclerosis
por: Törnell, Andreas, et al.
Publicado: (2022)

Maintenance Therapy in AML
por: Reville, Patrick K., et al.
Publicado: (2021)

P411: LONGITUDINAL CHARACTERIZATION OF MOLECULAR VARIANTS AT REMISSION AND RELAPSE: SUBANALYSIS OF THE QUAZAR AML-001 TRIAL
por: Lopes De Menezes, Daniel, et al.
Publicado: (2023)

Assessment of the consistency and robustness of results from a multicenter trial of remission maintenance therapy for acute myeloid leukemia
por: Buyse, Marc, et al.
Publicado: (2011)

The Innate Immune Cross Talk between NK Cells and Eosinophils Is Regulated by the Interaction of Natural Cytotoxicity Receptors with Eosinophil Surface Ligands
por: Pesce, Silvia, et al.
Publicado: (2017)

A new adult AML case with an extremely complex karyotype, remission and relapse combined with high hyperdiploidy of a normal chromosome set in secondary AML
por: Wafa, Abdulsamad, et al.
Publicado: (2018)

P1426: WU-NK-101, AN ALLOGENEIC MEMORY NK CELL, FOR THE TREATMENT OF RELAPSE OR REFRACTORY (R/R) ACUTE MYELOID LEUKEMIA (AML)
por: Muth, J. J., et al.
Publicado: (2022)

An adjuvant-containing cDC1-targeted recombinant fusion vaccine conveys strong protection against murine melanoma growth and metastasis
por: Arabpour, Mohammad, et al.
Publicado: (2022)

Role of Immunomodulation of BCG Therapy on AML Remission
por: Kennedy, Alice, et al.
Publicado: (2021)

Dactinomycin induces complete remission associated with nucleolar stress response in relapsed/refractory NPM1-mutated AML
por: Gionfriddo, Ilaria, et al.
Publicado: (2021)

Olutasidenib (FT-2102) induces durable complete remissions in patients with relapsed or refractory IDH1-mutated AML
por: de Botton, Stéphane, et al.
Publicado: (2023)

TIM-3 levels correlate with enhanced NK cell cytotoxicity and improved clinical outcome in AML patients
por: Rakova, Jana, et al.
Publicado: (2021)

Effective treatment with rituximab for the maintenance of remission in frequently relapsing minimal change disease
por: Papakrivopoulou, Eugenia, et al.
Publicado: (2016)

Mosquito Bite-Induced Localized NK/T-Cell Lymphoma Relapsed in a Patient with Complete Remission of Extranodal NK/T-Cell Lymphoma, Nasal Type
por: Kondo, Makoto, et al.
Publicado: (2019)

Isolated limb perfusion with melphalan activates interferon-stimulated genes to induce tumor regression in patients with melanoma in-transit metastasis
por: Johansson, Junko, et al.
Publicado: (2019)

Transient and durable T cell reactivity after COVID-19
por: Martner, Anna, et al.
Publicado: (2022)

Induction and subsequent decline of S1-specific T cell reactivity after COVID-19 vaccination
por: Törnell, Andreas, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_n1puj7re4huugt0b5o129qrtoq